Evidence map›Paper›PMID 17522232›Full record

ArticleJournal of virology2007

Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.

Hiroaki Takeuchi, Alicia Buckler-White, Ritu Goila-Gaur, Eri Miyagi, Mohammad A Khan, Sandrine Opi, Sandra Kao, Elena Sokolskaja, Thomas Pertel, Jeremy Luban and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Cyclophilin A and viral infections.Biochemical and biophysical research communications · 2012
    Review
  6. Article
  7. Article
  8. SIV replication in human cells.Frontiers in microbiology · 2012
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hiroaki TakeuchiLaboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, NIH, Building 4, Room 310, 4 Center Drive, MSC 0460, Bethesda, Maryland 20892-0460, USA.
Alicia Buckler-White
Ritu Goila-Gaur
Eri Miyagi
Mohammad A Khan
Sandrine Opi
Sandra Kao
Elena Sokolskaja
Thomas Pertel
Jeremy Luban
Klaus Strebel
National Institute of Allergy and Infectious Diseases · USColumbia University · US

Funding

Gag and Cyclophillin in HIV-1 ReplicationR01AI036199 · NIAID · UNIVERSITY OF GENEVA · PI LUBAN, JEREMY · 1994 to 2008
$2.9M
Molecular Analysis Of Retroviral Genes &Their ProductsZ01AI000669 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI STREBEL, KLAUS · 1993 to 2008
$852k
Intramural NIH HHSNIAID NIH HHS R01 AI036199NIAID NIH HHS R01AI36199
6 · The paper itself

Abstract

Vif is a primate lentiviral accessory protein that is crucial for viral infectivity. Vif counteracts the antiviral activity of host deaminases such as APOBEC3G and APOBEC3F. We now report a novel function of African green monkey simian immunodeficiency virus (SIVagm) Vif that promotes replication of SIVagm in human cells lacking detectable deaminase activity. We found that cyclophilin A (CypA) was excluded from wild-type SIV particles but was efficiently packaged into vif-deficient SIVagm virions. The presence of CypA in vif-defective SIVagm was correlated with reduced viral replication. Infection of CypA knockout Jurkat cells or treatment of Jurkat cells with cyclosporine A eliminated the Vif-sensitive inhibition and resulted in replication profiles that were similar for wild-type and vif-deficient SIVagm. Importantly, the inhibitory effect of CypA was restricted to virus-producing cells and was TRIM5alpha independent. The abilities of SIVagm Vif to inhibit encapsidation of CypA and to increase viral infectivity were shared by rhesus macaque SIV Vif and thus seem to be general properties of SIV Vif proteins. Exclusion of CypA from SIVagm particles was not associated with intracellular degradation, suggesting a mode of Vif action distinct from that proposed for APOBEC3G. This is the first report of a novel vif-sensitive antiviral activity of human CypA that may limit zoonotic transmission of SIV and the first demonstration of CypA encapsidation into a virus other than human immunodeficiency virus type 1.

Indexed as

AnimalsAntiviral Restriction FactorsCarrier ProteinsCell LineCyclophilin ACyclosporineGene Products, vifHumansImmunosuppressive AgentsSimian Immunodeficiency VirusTripartite Motif ProteinsUbiquitin-Protein LigasesVirionVirus ReplicationAntiviral Restriction FactorsCarrier ProteinsCyclophilin ACyclosporineGene Products, vifImmunosuppressive AgentsTRIM5 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID17522232
PMCPMC1951326
OpenAlexW2028086360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.